이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Precigen 관리

관리 기준 확인 2/4

Precigen's CEO는 Helen Sabzevari, Jan2020 에 임명되었습니다 의 임기는 4.58 년입니다. 총 연간 보상은 $ 3.72M, 26.9% 로 구성됩니다. 26.9% 급여 및 73.1% 보너스(회사 주식 및 옵션 포함). 는 $ 2.51M 가치에 해당하는 회사 주식의 0.77% 직접 소유합니다. 2.51M. 경영진과 이사회의 평균 재임 기간은 각각 4.6 년과 10.3 년입니다.

주요 정보

Helen Sabzevari

최고 경영자

US$3.7m

총 보상

CEO 급여 비율	26.9%
CEO 임기	4.7yrs
CEO 소유권	0.8%
경영진 평균 재임 기간	4.7yrs
이사회 평균 재임 기간	10.4yrs

최근 관리 업데이트

Recent updates

Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Apr 18

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Nov 10

Precigen names Rutul Shah as chief operating officer

Sep 21

Circling Back On Precigen

Aug 23

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Aug 10

Precigen Q2 2022 Earnings Preview

Aug 07

Precigen to sell Trans Ova Genetics for $170M upfront

Jul 05

Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

May 10

The Prognosis On Precigen

Jan 05

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Dec 31

CEO 보상 분석

Helen Sabzevari 의 보수는 Precigen 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$135m
Mar 31 2024	n/a	n/a	-US$97m
Dec 31 2023	US$4m	US$1m	-US$96m
Sep 30 2023	n/a	n/a	-US$85m
Jun 30 2023	n/a	n/a	-US$73m
Mar 31 2023	n/a	n/a	-US$79m
Dec 31 2022	US$3m	US$1m	-US$80m
Sep 30 2022	n/a	n/a	-US$84m
Jun 30 2022	n/a	n/a	-US$103m
Mar 31 2022	n/a	n/a	-US$108m
Dec 31 2021	US$3m	US$1m	-US$111m
Sep 30 2021	n/a	n/a	-US$124m
Jun 30 2021	n/a	n/a	-US$125m
Mar 31 2021	n/a	n/a	-US$110m
Dec 31 2020	US$20m	US$1m	-US$104m
Sep 30 2020	n/a	n/a	-US$100m
Jun 30 2020	n/a	n/a	-US$122m
Mar 31 2020	n/a	n/a	-US$138m
Dec 31 2019	US$1m	US$500k	-US$169m
Sep 30 2019	n/a	n/a	-US$373m
Jun 30 2019	n/a	n/a	-US$381m
Mar 31 2019	n/a	n/a	-US$414m
Dec 31 2018	US$3m	US$500k	-US$375m

보상 대 시장: Helen 의 총 보상 ($USD 3.72M )은 US 시장( $USD 2.41M ).

보상과 수익: 회사가 수익성이 없는 동안 Helen 의 보상이 증가했습니다.

CEO

Helen Sabzevari (62 yo)

4.7yrs

테뉴어

US$3,719,061

보상

Dr. Helen Sabzevari, Ph.D. MPH, served as Independent Director at Kinnate Biopharma Inc. from June 2021 to April 3, 2024. She has been President and Chief Executive Officer of Precigen, Inc (formerly Intre...

리더십 팀

이름	위치	테뉴어	보상	소유권
Randal Kirk	Executive Chairman	16.6yrs	US$600.00k	0.40% $ 1.1m
Helen Sabzevari	President	4.7yrs	US$3.72m	0.77% $ 2.1m
Harry Thomasian	Chief Financial Officer	2.9yrs	US$1.13m	0.080% $ 217.1k
Rutul Shah	Chief Operating Officer	no data	US$1.04m	0.073% $ 198.5k
Donald Lehr	Chief Legal Officer & Corporate Secretary	13.7yrs	US$1.06m	0.19% $ 509.3k
Jeffrey Perez	Senior Vice President of Intellectual Property Affairs	10.1yrs	US$872.09k	0.26% $ 703.3k
Steven Harasym	VP & Head of Investor Relations	6.7yrs	데이터 없음	데이터 없음
Rob Russell	VP & Head of Human Resources	no data	데이터 없음	데이터 없음
Douglas Brough	Senior VP & Head of Research	no data	데이터 없음	데이터 없음
Bryan Butman	Senior VP & Head of CMC	no data	데이터 없음	데이터 없음
Amy Lankford	Senior VP & Head of Clinical Operations and Regulatory Affairs	1.3yrs	데이터 없음	데이터 없음
Phil Tennant	Chief Commercial Officer	less than a year	데이터 없음	데이터 없음

4.7yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 관리: PGEN 의 관리팀은 경험 ( 4.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Randal Kirk	Executive Chairman	16.6yrs	US$600.00k	0.40% $ 1.1m
Helen Sabzevari	President	4.3yrs	US$3.72m	0.77% $ 2.1m
Jeffrey Kindler	Independent Director	12.8yrs	US$319.00k	0.14% $ 372.3k
Fred Hassan	Independent Director	8.3yrs	US$306.50k	0.36% $ 974.7k
Cesar Alvarez	Independent Director	16.6yrs	US$312.50k	0.20% $ 539.4k
James Turley	Lead Independent Director	10.4yrs	US$312.50k	0.16% $ 447.2k
Steven Frank	Independent Director	16.6yrs	US$300.00k	0.36% $ 969.4k
Nancy Agee	Independent Director	less than a year	데이터 없음	0.0061% $ 16.7k
Vinita Gupta	Independent Director	7.4yrs	US$306.50k	0.16% $ 431.2k

10.4yrs

평균 재임 기간

69yo

평균 연령

경험이 풍부한 이사회: PGEN 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.3 년).

Precigen 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Precigen, Inc. Announces the Appointment of Phil Tennant as Chief Commercial Officer

Precigen, Inc., Annual General Meeting, Jul 05, 2024

President exercised options and sold US$575k worth of stock

Independent Director recently sold US$136k worth of stock

Independent Director recently bought US$688k worth of stock

President exercised options and sold US$58k worth of stock

Recent updates

Consensus revenue estimates fall by 12%

Price target decreased by 41% to US$6.00

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q2, 2024 Results on Aug 14, 2024

New minor risk - Shareholder dilution

Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

Precigen, Inc. has filed a Follow-on Equity Offering in the amount of $30 million.

New minor risk - Share price stability

Precigen, Inc. Announces the Appointment of Phil Tennant as Chief Commercial Officer

Price target increased by 11% to US$10.12

Precigen, Inc. Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More Than Half of Patients Achieved Complete Response

Price target increased by 11% to US$10.12

Precigen, Inc., Annual General Meeting, Jul 05, 2024

Consensus revenue estimates fall by 10%

Price target increased by 40% to US$9.12

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q1, 2024 Results on May 14, 2024

Price target decreased by 27% to US$6.50

Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy

President exercised options and sold US$575k worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q4, 2023 Results on Mar 19, 2024

We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Precigen: RRP Targeting With AdenoVerse Technology Platform

Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Independent Director recently sold US$136k worth of stock

Forecast to breakeven in 2026

Consensus revenue estimates fall by 11%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

Independent Director recently bought US$688k worth of stock

Consensus revenue estimates decrease by 12%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen, Inc Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

President exercised options and sold US$58k worth of stock

Precigen, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Precigen, Inc. Receives Breakthrough Therapy Designation for PRGN- 2012 Adenoverse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers

Precigen, Inc. Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer

Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen, Inc. to Report Q1, 2023 Results on May 10, 2023

Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Precigen, Inc. Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference

Precigen, Inc. Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients

Insufficient new directors

Price target increased to US$14.50

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Precigen, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Precigen, Inc. Appoints Rutul R. Shah as Chief Operating Officer, Effective October 1, 2022

Precigen names Rutul Shah as chief operating officer

Chief Financial Officer recently bought US$51k worth of stock

Circling Back On Precigen

Independent Director recently sold US$115k worth of stock

Consensus revenue estimates fall by 66%

Independent Director notifies of intention to sell stock

Price target decreased to US$12.00

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen Q2 2022 Earnings Preview

Price target increased to US$13.75

Precigen, Inc. to Report Q2, 2022 Results on Aug 08, 2022

URUS Group LP agreed to acquire Trans Ova Genetics LC from Precigen, Inc. (NasdaqGS:PGEN) for $180 million.

Precigen to sell Trans Ova Genetics for $170M upfront